This approval represents initiation of the first clinical sites for the pivotal study and permits commencement of screening for suitable patients. This approval is claimed to be the first in seven countries within which the company will be conducting the Phase III trial of Generex Oral-lyn.
The protocol calls for a trial with a six month active treatment period and a six month follow up which is expected to include up to 750 patients with type-1 diabetes mellitus.